Janus Kinase (JAK) inhibitors (e.g., Tofacitinib)

Type: drug

Status: Investigational (for DM)

Developer: Pfizer (Tofacitinib)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026